Astrazeneca (AZN) Net Income towards Common Stockholders (2009 - 2026)

Astrazeneca has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $2.5 billion in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 2.33% year-over-year to $2.5 billion in Q2 2026; TTM through Jun 2026 was $10.4 billion, a 25.93% increase from a year earlier, with the FY2025 full-year figure at $5.4 billion, up 121.09% from the prior year.
• Net Income towards Common Stockholders was $2.5 billion for Q2 2026 at Astrazeneca, down from $3.1 billion in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $3.1 billion in Q1 2026, with the low at $360.0 million in Q2 2022.
• Average Net Income towards Common Stockholders over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 596.97% in 2022 against a maximum downside of 75.27% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at $901.0 million in 2022, then gained by 6.55% to $960.0 million in 2023, then soared by 56.25% to $1.5 billion in 2024, then surged by 55.07% to $2.3 billion in 2025, then rose by 7.78% to $2.5 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $2.5 billion (Q2 2026), $3.1 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.